PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary BGI and OpGen Collaborate on Use of Optical Mapping for Whole Genome Assembly - See more at: http://opgen.com/news/press-releases#sthash.IZ7mrxlV.dpuf
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 Gaithersburg, Md. – November 4, 2010 – BGI, the largest genomics organization in the world, and OpGen, Inc., a commercial phase genomics company and exclusive provider of Optical Mapping Technology, announced their joint effort to
View HTML
Toggle Summary Data Show “Super Bug” Surveillance System Based on OpGen’s Acuitas(R) Resistome Test Can Identify Potential Outbreaks in Hospitals and Improve Infection Control  
Researchers From Rush University Medical Center Present Data at IDWeek 2015 GAITHERSBURG, Md. , Oct. 12, 2015 (GLOBE NEWSWIRE) --   OpGen, Inc. (NASDAQ:OPGN), an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a study with its Acuitas ®
View HTML
Toggle Summary District of Columbia Hospital Association Chooses OpGen to Create Citywide Effort to Track Multidrug-Resistant Bacteria
DC’s Public Health Agencies, Healthcare Facilities to Examine Occurrence of “Superbugs” in First-of-Its-Kind Evaluation, Supported by the Centers for Disease Control & Prevention GAITHERSBURG, Md. and WASHINGTON , Nov. 18, 2015 (GLOBE NEWSWIRE) -- OpGen, Inc.
View HTML
Toggle Summary Fluidigm and OpGen Enter Into Strategic Agreement to Develop Multi-Drug Resistance Testing Kits and Equipment
Five-Year Agreement Expands on Prior Supply Agreement SOUTH SAN FRANCISCO, Calif. and GAITHERSBURG, Md. , July 13, 2015 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and OpGen, Inc. (NASDAQ:OPGN) today announced an expanded relationship and new agreement that includes collaborating on the
View HTML
Toggle Summary Frost & Sullivan New Product Innovation Award Recognizes OpGen’s Argus® Whole Genome Mapping System
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279 GAITHERSBURG, Md.–(BUSINESS WIRE)–OpGen, Inc., a provider of innovative whole genome DNA analysis solutions, announced today the
View HTML
Toggle Summary Hitachi High-Technologies Corporation and OpGen Announce Early Access Program for Human Chromosome Mapping Analytical Service
Companies to Introduce Human Chromosome Explorer SM Cloud-Based Informatics and Data Management Platform Tokyo and Gaithersburg, Md.—October 19, 2014 — Hitachi High-Technologies Corporation and OpGen, Inc. , a leading genetic analysis company, today announced the introduction of an Early Access
View HTML
Toggle Summary Large Integrated Health Outcomes Study Reveals Shifting Epidemiology In Drug Resistant Organisms
SALT LAKE CITY and GAITHERSBURG, Md. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- A first-of-its-kind study of 900,000 hospital admissions from an integrated health system has yielded insights into shifts in the epidemiology of multi-drug resistant organisms (MDROs) in the community.
View HTML
Toggle Summary Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies
Media Contant: Dan Budwick Pure Communications, Inc. (973) 271-6085 OpGen Contact: Judy Macemon VP Marketing, OpGen, Inc. (240) 813-1279 Companies to develop improved microbial analysis and surveillance systems for public health and infectious disease markets CARLSBAD, Calif. and GAITHERSBURG, Md.
View HTML
Toggle Summary New Study Data Show OpGen’s QuickFISH® Blood Culture Pathogen ID Tests to be Rapid and Cost-Effective, with Utility to Inform Antimicrobial Stewardship Decisions
Company to preview automated QuickFISH Digital Imager at 26th European Congress of Clinical Microbiology and Infectious Diseases GAITHERSBURG, Md. , April 11, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat
View HTML
Toggle Summary OpGen Acuitas® MDRO Gene Test Approved by NY State Department of Health
GAITHERSBURG, Md. , July 12, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that the New York State Department of Health (NYSDOH) has approved the Acuitas® MDRO Gene Test for use by physicians and healthcare providers in the state. The approval of OpGen’s CLIA laboratory to
View HTML